Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408997 | 0.81 | MAPT (0.46) | MAOBMAOAMEN1LMNAMAPT | |
| SCHEMBL3965716 | 0.81 | MEN1 (0.45) | MAOBMAOATRPV4CYP11B1CYP11B2 | |
| SCHEMBL30826239 | 0.79 | SMN1; SMN2 (0.49) | MAOBMEN1LMNAMAPTKMT2A | |
| SCHEMBL28303519 | 0.77 | PLA2G7 (0.46) | MAOBMAOAMEN1LMNAMAPT | |
| SCHEMBL21728104 | 0.77 | ALDH1A1 (0.46) | MAOBMAOAMEN1LMNAMAPT | |
| SCHEMBL5901307 | 0.77 | MAOB (0.48) | ARMAOBMAOACYP11B1CYP11B2 | |
| SCHEMBL23795076 | 0.76 | MAOB (0.53) | ARMAOBMAOAMEN1LMNA | |
| SCHEMBL13223331 | 0.75 | CYP11B1 (0.51) | MRGPRX4ARMAOBTRPV4CYP11B1 | |
| SCHEMBL2478120 | 0.75 | MAOB (0.42) | MAOBTRPV4ADRA2AADRA2BADRA2C | |
| SCHEMBL30580547 | 0.75 | AR (0.50) | MRGPRX4ARMAOBTRPV4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-0888327-B1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2002-06-12 | — | — | EP | disclosed |
| US-5990142-A | ANTIINFLAMMATORY AGENTS AND ANTIALLERGENS HAVING GOOD ORAL ADSORPTION AND BIOAVAILABILITY; CARDIOTONIC AND ANTIISCHEMIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1999-11-23 | — | — | US | disclosed |
| EP-0888327-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034885-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | MRGPRX4 55/4885AR 1046/4885MAOB 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.